Minerva Neurosciences, Inc.
NERV
$5.21
-$0.29-5.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -57.75% | 14.20% | -10.09% | 20.41% | 56.84% |
| Gross Profit | 57.75% | -14.20% | 10.09% | -20.41% | -56.84% |
| SG&A Expenses | -6.09% | -7.98% | -3.83% | -2.53% | -4.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.87% | -40.23% | -38.32% | -22.02% | -5.50% |
| Operating Income | 30.87% | 40.23% | 38.32% | 22.02% | 5.50% |
| Income Before Tax | -20,492.20% | -323.59% | 133.38% | 119.79% | 104.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20,492.20% | -323.59% | 133.38% | 119.79% | 104.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20,492.20% | -323.59% | 133.38% | 119.79% | 104.80% |
| EBIT | 30.87% | 40.23% | 38.32% | 22.02% | 5.50% |
| EBITDA | 30.88% | 40.23% | 38.33% | 22.02% | 5.50% |
| EPS Basic | -14,199.47% | -323.59% | 133.38% | 118.44% | 104.08% |
| Normalized Basic EPS | -14,212.89% | -323.55% | 133.37% | 118.44% | 104.08% |
| EPS Diluted | -14,533.55% | -318.52% | 133.27% | 118.34% | 103.99% |
| Normalized Diluted EPS | -14,212.89% | -323.55% | 133.37% | 118.44% | 104.08% |
| Average Basic Shares Outstanding | 11.72% | 0.00% | 0.00% | 7.29% | 16.49% |
| Average Diluted Shares Outstanding | 11.72% | 0.00% | 0.00% | 7.29% | 16.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |